Many women rely on annual mammograms for peace of mind. Getting a “normal” result usually means you can breathe easy for another year. However, in some cases, a clear result can be misleading.
If you received a clean bill of health only to receive a breast cancer diagnosis much later, the issue might be dense breast tissue. Understanding how this biological factor impacts testing is crucial for understanding your legal rights regarding a delayed diagnosis.
What is dense breast tissue?
Breast anatomy consists of three main components: fatty tissue, fibrous connective tissue and glandular tissue. When a patient is said to have “dense” breasts, it simply means they possess higher levels of fibrous and glandular tissue compared to fatty tissue.
It is important to understand that this is a biological characteristic, not a medical condition or disease. It is also quite prevalent. According to the National Cancer Institute, nearly 50% of women over the age of 40 have dense breast tissue. Despite being common, this density poses a challenge for radiologists.
Why tumors can be more difficult to spot
On a mammogram, fatty tissue appears dark, providing a clear background where white tumors stand out easily. Dense tissue, however, appears solid white, just like tumors and calcifications. This lack of contrast means a tumor can easily blend in with healthy dense tissue, making standard mammograms more likely to miss cancer in these patients.
Because of these known risks, the Food and Drug Administration (FDA) updated their regulations to require mammography providers to inform women if they have dense breast tissue. Moreover, the medical standard of care often requires doctors to assess whether supplemental screening is necessary for these patients.
Why this matters for your medical care
If a radiologist identifies your density as “heterogeneously dense” or “extremely dense” (BI-RADS categories C or D), a doctor should evaluate your risk factors to determine if additional screening is appropriate. This may include an ultrasound or an MRI.
These tools are vital because they can detect what a mammogram misses. When a doctor skips this evaluation, cancer may grow undetected, leading to more difficult treatments later. If accepted medical standards called for additional screening, a doctor’s failure to order those tests may constitute negligence under New York law.
Did negligence play a role?
Living with a delayed diagnosis raises difficult questions about negligence and potential medical malpractice. To answer them, you must look at whether your provider ignored critical information such as breast tissue density. Consulting with a legal professional can provide the clarity you need.